Gilead Sciences Gross Margin 2006-2021 | GILD

Current and historical gross margin for Gilead Sciences (GILD) over the last 10 years. The current gross profit margin for Gilead Sciences as of September 30, 2021 is %.
Gilead Sciences Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2021-09-30 $27.48B $22.11B 80.45%
2021-06-30 $26.64B $21.35B 80.14%
2021-03-31 $25.56B $20.60B 80.58%
2020-12-31 $24.69B $20.12B 81.48%
2020-09-30 $23.15B $18.29B 79.02%
2020-06-30 $22.17B $17.42B 78.57%
2020-03-31 $22.72B $18.03B 79.37%
2019-12-31 $22.45B $17.77B 79.18%
2019-09-30 $22.37B $17.80B 79.60%
2019-06-30 $22.36B $17.74B 79.37%
2019-03-31 $22.32B $17.51B 78.45%
2018-12-31 $22.13B $17.27B 78.07%
2018-09-30 $22.28B $17.74B 79.63%
2018-06-30 $23.20B $18.71B 80.67%
2018-03-31 $24.69B $20.28B 82.12%
2017-12-31 $26.11B $21.74B 83.26%
2017-09-30 $27.48B $23.29B 84.75%
2017-06-30 $28.47B $24.18B 84.94%
2017-03-31 $29.10B $25.08B 86.17%
2016-12-31 $30.39B $26.13B 85.98%
2016-09-30 $31.58B $27.33B 86.55%
2016-06-30 $32.37B $28.19B 87.08%
2016-03-31 $32.84B $28.52B 86.85%
2015-12-31 $32.64B $28.63B 87.73%
2015-09-30 $31.45B $27.44B 87.26%
2015-06-30 $29.19B $25.26B 86.54%
2015-03-31 $27.49B $23.63B 85.97%
2014-12-31 $24.89B $21.10B 84.78%
2014-09-30 $20.70B $17.11B 82.69%
2014-06-30 $17.44B $14.16B 81.20%
2014-03-31 $13.67B $10.63B 77.78%
2013-12-31 $11.20B $8.34B 74.48%
2013-09-30 $10.67B $7.99B 74.91%
2013-06-30 $10.31B $7.72B 74.86%
2013-03-31 $9.95B $7.43B 74.62%
2012-12-31 $9.70B $7.23B 74.53%
2012-09-30 $9.31B $6.94B 74.46%
2012-06-30 $9.01B $6.70B 74.33%
2012-03-31 $8.74B $6.51B 74.49%
2011-12-31 $8.39B $6.26B 74.67%
2011-09-30 $8.18B $6.15B 75.11%
2011-06-30 $8.00B $6.02B 75.21%
2011-03-31 $7.79B $5.89B 75.56%
2010-12-31 $7.95B $6.08B 76.47%
2010-09-30 $7.98B $6.14B 76.86%
2010-06-30 $7.85B $6.07B 77.34%
2010-03-31 $7.57B $5.86B 77.45%
2009-12-31 $7.01B $5.42B 77.26%
2009-09-30 $6.41B $4.96B 77.49%
2009-06-30 $5.98B $4.64B 77.69%
2009-03-31 $5.61B $4.39B 78.31%
2008-12-31 $5.34B $4.21B 78.88%
2008-09-30 $5.00B $3.98B 79.57%
2008-06-30 $4.69B $3.77B 80.36%
2008-03-31 $4.46B $3.62B 81.21%
2007-12-31 $4.23B $3.46B 81.82%
2007-09-30 $4.03B $3.33B 82.45%
2007-06-30 $3.72B $3.11B 83.38%
2007-03-31 $3.36B $2.85B 84.71%
2006-12-31 $3.03B $2.59B 85.69%
2006-09-30 $2.74B $2.38B 87.13%
2006-06-30 $2.48B $2.17B 87.62%
2006-03-31 $2.29B $2.00B 87.25%
2005-12-31 $2.03B $1.77B 87.22%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $84.382B $24.689B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.747B 8.96
Bio-Rad Laboratories (BIO.B) United States $17.038B 34.58
QIAGEN (QGEN) Netherlands $10.791B 18.27
Biohaven Pharmaceutical Holding (BHVN) United States $7.896B 0.00
Emergent Biosolutions (EBS) United States $2.380B 8.56
Arcus Biosciences (RCUS) United States $2.057B 0.00
Myovant Sciences (MYOV) United Kingdom $1.157B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.011B 0.00
Zymeworks (ZYME) Canada $0.386B 0.00
Ambrx Biopharma (AMAM) United States $0.188B 0.00
SQZ Biotechnologies (SQZ) United States $0.178B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.88